Turning a blind eye:Why we don't test for blindness at the end of our trialsBMJ 2004; 328 doi: https://doi.org/10.1136/bmj.328.7448.1136-a (Published 06 May 2004) Cite this as: BMJ 2004;328:1136
- David L Sackett, trialist (firstname.lastname@example.org)
- Trout Research and Education Centre at Irish Lake, RR 1, Markdale, ON, Canada N0C 1H0
EDITOR—I write with reference to the paper by Fergusson et al.1 Asking patients or their clinicians at the end of a trial which drug they think they were taking confounds failures in blinding with successes in pre-trial hunches about efficacy.
Thirty years ago, at the end of the first ever trial of aspirin and sulfinpyrazone …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial